Original Source(s)
Related Content
FDA expands essential thrombocythemia care
Phase 3 SURPASS ET data showed higher durable response rates with ropeginterferon alfa-2b-njft than with anagrelide.
September 1, 2026
-
2 min
Estriol may ease menopause-related cognitive decline
Women reported improvement across 6 cognitive domains during 12 months of estriol-based treatment, while murine models suggested a potential astrocyte-mediated mechanism.
September 3, 2026
-
3 min